Health and Life Sciences | AI Goes from Pilot to Operating Model | PiTech Solutions Podcast

Health and Life Sciences | AI Goes from Pilot to Operating Model | PiTech Solutions PodcastTwenty twenty-six is the year AI in Health and Life Sciences stops being a strategy slide and becomes the operating model. In this episode, Mike and Laura unpack five forces redefining how new medicines are discovered, tested, and approved, and what C-suite leaders in regulated industries should be doing right now.FDA and EMA Align on AI Principles. The FDA January twenty twenty-six guiding principles, the joint FDA EMA agreement on AI in drug development, and the final FDA guidance expected this quarter mean the grace period for ad hoc AI governance is over. Boards now have a clearer global compliance roadmap, but production grade controls are mandatory.Capital Floods Into AI Drug Discovery. The Eli Lilly Insilico Medicine deal worth up to two point seven five billion dollars headlines a market with more than one hundred seventy AI originated drug programs in clinical development. McKinsey estimates sixty to one hundred ten billion dollars in annual value across the pharma value chain, but only for organizations that have rebuilt their data foundation.Digital Twins and Synthetic Control Arms. AI generated digital twins are reducing trial size, compressing timelines, and limiting placebo exposure. A recent Alzheimer study showed a potential ten percent sample size reduction and tens of millions in savings, with the FDA now providing a regulatory anchor through its twenty twenty-six guidance.EU AI Act and the Biotech Act. High risk AI systems must show full EU AI Act compliance by August of twenty twenty-six, with a one year extension for AI as a medical device safety component. Combined with the EU Biotech Act, the Clinical Trials Regulation updates, and EHDS, European compliance leaders are managing one of the most complex regulatory transitions in a decade.AI Powered CRISPR and Personalized Medicine. From OpenCRISPR one to the bespoke in vivo CRISPR therapy delivered to an infant in six months, AI is collapsing the timeline for personalized gene therapy. This forces commercial, manufacturing, and reimbursement models to evolve in lockstep with the science.To learn how PiTech Solutions helps regulated industry leaders bring AI strategy, data modernization, and regulatory readiness into a single executable program, visit pitechsol.com.#HealthAndLifeSciences #AIinPharma #DigitalTwins #EUAIAct #PersonalizedMedicine